Company news

IRLAB Therapeutics AB news in 2025

IRLAB Therapeutics AB's news releases, calls and decks from 2025, newest first.

View company

IRLAB Receives Approval for a Phase Ib Study with IRL757 in Parkinson's Disease

December 23, 2025

The European Patent Office Intends to Grant a New Patent for IRLAB's Mesdopetam

December 11, 2025

IRLAB Appoints Gustaf Albèrt as the New Chief Financial Officer

October 9, 2025

IRLAB Progresses Fully Funded IRL757 Study in Parkinson's Disease in Partnership with MSRD

October 2, 2025

IRLAB Is Granted a Patent Strengthening the Market Exclusivity of The Drug Candidate Mesdopetam in China

September 4, 2025

IRLAB Appoints Roy Jonebrant as Interim CFO

August 21, 2025

IRLAB Reports Positive Results from the Second Part of a Phase I Study with IRL757

May 28, 2025

IRLAB is Granted a Patent Expanding the Patent Protection for the Drug Candidate Mesdopetam in the US

May 13, 2025

Calls in 2025

Decks in 2025